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Copyright © 2006 AHC Protein kinase C (PKC) is a key enzyme that participates in various neuronal functions. PKC
has also been identified as a target molecule for general anesthetic actions. Raf, mitogen-
activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK1/2) have
been thought to be target effectors of PKC. In the present study, we attempted to evaluate
the effect of sevoflurane on PKC/MAPK cascade signaling in cultured fetal rat cerebral
cortex neurons, prepared from embryonic day 18 fetuses. The effects of sevoflurane on the
translocation of 7 PKC isoforms (α, βI, βII, γ, δ, ε and ζ) were observed by immunoblotting
using isoform-selective antibodies to PKCs. The treatment of neurons with sevoflurane in-
duced the translocation of PKC α and PKC βII species from the cytosol to the membrane
fraction, which indicated the activation of these PKC isoforms. In contrast, there was no clear
change in the distribution of other PKC isoforms. We next examined whether the specific ac-
tivation of PKC α and βII by sevoflurane could stimulate the MAP kinase signaling pathway
in cultured neurons. Raf phosphorylation was increased by the administration of 0.25 mM
sevoflurane. The phosphorylation of Raf proteins reached a maximum at 5–10 min. Subse-
quently, the phosphorylation of MEK proteins was increased at 10–15 min after sevoflurane
treatments. That of ERK proteins was induced at 15–60 min. Moreover, the phosphorylation
of ERK induced by sevoflurane was significantly decreased by the treatment of PKC inhibitor
(staurosporine) and MEK inhibitor (PD98059). On the other hand, the contents of total Raf,
MEK and ERK proteins were relatively constant at all times examined. To examine the
localization of phosphorylated-ERK protein, immunohistochemical staining of sevoflurane-
treated cultured neurons was performed. The phosphorylated-ERK proteins were markedly
accumulated in both the cytosol of the cell body and the neurites in the neuronal cells with
time after 0.25 mM sevoflurane-treatment. These results demonstrated that sevoflurane in-
duced the phosphorylation of the MAP kinase cascade through the activation of the PKC α
and PKC βII species.
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I. Introduction
The protein kinase C (PKC) family consists of more
than 11 phospholipid-dependent serine/threonine kinases
which take part in cellular responses to various agonists,
including hormones, some growth factors and neurotrans-
mitters [1, 2, 16, 17, 25]. PKC is abundant in the central ner-
vous system and plays an important role in the regulation
of neuronal functions [22, 26]. Many studies have demon-
strated that PKC may participate as a potential target mole-
cule in general anesthetic actions [8, 15]. Halothane and pro-
pofol stimulate the activation of rat partial purified PKC in
the presence of physiologically relevant bilayer vesicles in
vitro [4]. Halothane also stimulates PKC activity in ratHasegawa et al. 164
cerebrocortical synaptosomes [6]. Although these reports
suggest that anesthetics may function in the brain through
PKC signal transduction, little is known about the detailed
effects of anesthetics on PKC signaling in neuronal cells.
Multiple discrete isoforms of PKC have been identi-
fied. These isoforms show subtly different enzymological
properties, differential tissue expression, and specific intra-
cellular localization [16, 18]. The PKC isoforms are divided
into the following three groups according to their sensitivity
toward the activators: conventional PKCs (cPKC: α, β1, β2,
γ) are calcium-dependent, and stimulated by DAG; novel
PKCs (nPKC: δ, ε, η, θ) are calcium-independent, but are
diacylglycerol (DAG)-stimulatable; atypical PKCs (aPKC:
ζ, µ) require neither calcium nor DAG for optimal activity.
Various reports have demonstrated that individual PKCs
mediate different biological processes in the cell. In the
physiological activation of cPKC isoforms by DAG, binding
of DAG increases the affinity of cPKC for Ca2+ and phos-
phatidylserine, facilitates cPKC translocation and binding to
cell membranes, and increases cPKC catalytic activity [30].
In cultured vascular smooth muscle cells, isoflurane, a vola-
tile anesthetic, evokes the translocation of PKC ε, but not
PKC α from the cytosol to the membrane fraction [29]. This
result suggests that anesthetics activate isotype-specific
PKC in vascular smooth muscle cells. Isoflurane also stimu-
lates the phosphorylation of extracellular signal-regulated
kinase (ERK) in smooth muscle cells [29]. ERK is a compo-
nent of the mitogen-activated protein (MAP) kinase signal-
ing pathway together with small G proteins such as Raf and
MAP kinase kinase (MEK). However it is not clear whether
isoflurane-induced ERK phosphorylation is mediated by the
Raf-MEK cascade. PKC is an important initiator of the MAP
kinase signaling pathway in the central nervous system [20].
However, it remains unclear which of the PKC isoforms are
specifically activated by volatile anesthetics in neuronal
cells.
Sevoflurane is most frequently used as a volatile anes-
thetic because it has a low blood-gas partition coefficient
and the lowest pungency of commercially available inhaled
anesthetics. In spite of the many investigations aimed at elu-
cidating sevoflurane function in recent years there are still
numerous unanswered questions concerning intercellular
signal transduction in neuronal cells. The purpose of this
study was to examine the effects of sevoflurane on the PKC-
MAP kinase signaling pathway in rat cerebral cortex cul-
tured neurons using biochemical and morphological proce-
dures. Our results indicated that treatment with sevoflurane
led specifically to activation of PKC α and βII followed by
the stimulation of MAP kinase signaling, accompanied by
the phosphorylation of ERK in the cell body and neurites of
neurons.
II. Materials and Methods
Materials
Sevoflurane was purchased from Abbott Japan (Tokyo,
Japan). DNase-I (D-4527), polyethyleneimine, Poly-L-
lysine (0.01% Solution); PD98059 and staurosporine from
Sigma Chemical Co. (St. Louis, MO); phosphate buffered
saline (PBS) from Dainippon Seiyaku (Osaka, Japan); α-
Minimum Essential medium (α-MEM) and horse serum
from Invitrogen Japan K.K. (Tokyo, Japan); neurobasal
medium and B27 supplement from Life Technologies
(Gaithersburg, MD); Lab-Tek Chamber Slides from Nalgen
Nunc International (Naperville, IL). Anti-Raf antibody and
anti-PKC antibody (α,  βI,  βII,  γ,  θ,  δ,  ε,  η,  ζ,  µ) were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Anti-phosphorylated-Raf (p-Raf), MEK, p-MEK, p-
ERK and ERK antibodies were purchased from New
England Biolabs, Inc. (Beverly, MA). Anti-mouse and anti-
rabbit antibodies labeled with horseradish peroxidase were
purchased from Amersham Biosciences (Piscataway, NJ).
Cell culture
The Tokai University Institutional Animal Care and
Use Committee approved all animal studies. Pregnant
Wistar-Imamichi rats were purchased from Imamichi Insti-
tute for Animal Reproduction, Tsukuba, Japan. Primary rat
cerebral cortex cultured neurons were established from
embryonic day 18 fetuses. Brains were aseptically excised
and septal tissue areas were dissected out with a pair of
scalpels. Dissociation was done under a stereomicroscope
according to the description of fetal rat brain anatomy. After
dissociation using 10 units/ml papain (Worthington Bio-
chemical Corp., Lakewood, NJ) and 0.01% DNase I, tissue
fragments were sedimented following the addition of a few
milliliters of horse serum. The pellet was resuspended in a
medium containing 5% (v/v) heat-inactivated horse serum
(HS, Gibco BRL, Grand Island, NY), 5% (v/v) precolostrum
newborn calf serum (Nakashibetsu Serum Center, Mitsu-
bishi Chemical Industry, Tokyo), α-MEM containing 1.9
mg/ml sodium bicarbonate, 100 U/ml penicillin and 100
µg/ml streptomycin sulfate. The cell suspension was passed
through two different sizes of plastic tips. Cells were
seeded onto polyethyleneimine-coated 60-mm plates at 106
cells/cm2. Surface coating was done by using a solution of
1 mg/ml polyethyleneimine in 150 mM sodium borate buf-
fer, pH 8.4, for 3 hr at room temperature. The plates were
washed twice with sterile distilled water and then twice with
serum-containing medium. They were cultured in a humidi-
fied 10% CO2-90% air atmosphere at 37°C, and the medium
was changed to neurobasal medium containing B-27 sup-
plement. Sevoflurane was dissolved in dimethyl sulfoxide
(DMSO). The final concentration of DMSO in each medium
was 0.1%. PD98059 and staurosporine was dissolved in
DMSO as 10 mM and 1 mM stock solution which, when
needed, were further diluted to reach final concentrations.
Assay of cell viability
Cell viability was determined by using a Cell Counting
Kit-8 (Dojindo Laboratories, Kumamoto, Japan). At the end
of the treatment period, 10 µl of 5 mM WST-8, 0.2 mM 1-
methoxy PMS, 150 mM NaCl was added to each well. The
plates were placed at 37°C for 4 hr in the dark and the absor-Sevoflurane Stimulates PKC/MAPK Signaling 165
bance at 450 nm was read using a Thermo Max microplate
reader (Molecular Devices Corp., Sunnyvale, CA, USA).
Usually four replicate wells were used for each group to be
tested. Wells containing medium but no cells served as
blanks. Sevoflurane concentrations of 0.25 and 0.5 mM cor-
respond to 0.3125 and 0.625 minimum alveolar concentra-
tions (MAC), respectively [10]. These concentrations are
lower than that of clinical usage.
Immunoblot analysis
Cells were lysed in 2 ml of ice-cold hypotonic lysis
buffer (10 mM HEPES-NaOH buffer at pH 7.4, 1 mM
EGTA, 1 mM EDTA, 1 mM dithiothreitol, 1 µg/ml leupep-
tin) by homogenization with a glass/Teflon homogenizer
with five up-and-down strokes. The homogenate was centri-
fuged at 200,000 g for 15 min at 4°C to yield supernatant
(“cytosol”) and pellet (“membrane”) fractions, which were
collected separately. The pellet fraction was resuspended
and homogenized in 1 ml of lysis buffer containing 0.5%
(v/v)  Nonidet P-40 and incubated on ice for 30 min to
extract PKC activity. After an additional 1 ml of lysis buffer
was added to decrease the detergent concentration, the pellet
was centrifuged at 200,000 g for 15 min at 4°C, and the
supernatant fraction was removed. Total protein content of
the supernatant and pellet solution was determined using
the Bio-Rad protein assay kit. In each experiment, samples
were tested at equal concentrations of total protein, which
ranged from 20 to 30 µg. Samples were boiled in sample
buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
10% 2-mercaptoethanol) and separated by SDS-PAGE
(10% polyacrylamide gels) and then electro-transferred to
nitrocellulose membranes. The nitrocellulose membranes
were blocked with 5% non-fat dry milk, 0.1% Tween 20 in
0.01 M Tris-buffered saline (TBS) for 1 hr at room tem-
perature. After three washes with 0.05% Tween 20 in 0.01
M phosphate buffered saline (T-PBS), the membranes were
incubated with antibodies against specific isoforms of PKC
(PKC α, βI, βII, γ, δ, ε and ζ at 1:400) for 1 hr at room tem-
perature. Membranes were washed five times with T-PBS
and incubated with horseradish peroxidase-conjugated
anti-rabbit Ig antibody diluted 1:5000 with T-PBS for 1 hr at
room temperature. After five washes with T-PBS, immuno-
reactive bands were detected using the enhanced chemi-
luminescence method (ECLplus Amersham Biosciences).
Quantitative analysis was performed using image analysis
software (NIH Image).
Cells were scraped in 0.1 M sodium phosphate buffer
(pH 6.8) containing 1% Triton X-100, 1 mM PMSF, 1
mg/ml aprotinin and 10 mg/ml leupeptin. Cell homogenates
were vortexed for 1 hr at 4°C and centrifuged at 12,000 g for
15 min. Protein quantification, separation by SDS-PAGE,
and immunoblotting were performed as described above
using primary antibody (anti-Raf, MEK, ERK1/2, pRaf,
pMEK and pERK1/2, diluted 1:400) and secondary antibody
(horseradish peroxidase-conjugated anti-mouse Ig and anti-
rabbit Ig antibodies, diluted 1:5000 with T-PBS).
Immunohistochemistry
Cells were cultured on Poly-L-lysine coated Lab-Tek
Chamber Slides. The slides were prefixed in 4% paraformal-
dehyde, 0.05% glutaraldehyde in 0.1 M cacodylate buffer,
pH 7.4, in a microwave oven for 45 sec at 35°C. They were
then fixed in 4% paraformaldehyde, 0.03% Triton X-100 in
0.1 M cacodylate buffer, pH 7.4, at 4°C for 1 hr. After ten
washes with 0.01 M PBS, the slides were incubated with
anti-phospho-ERK antibody diluted 1:400 with 3% BSA-
PBS containing 0.03% Triton-X-100 at 4°C for 12 hr. After
ten washes with 0.01 M PBS, the slides were incubated with
anti-mouse IgG Alexa-488 antibody diluted 1:200 with 1%
BSA-PBS containing 0.03% Triton-X-100 at 4°C for 12 hr.
After ten washes with 0.01 M PBS, the slides were examined
with a confocal laser scanning microscopy (LSM-410, Carl
Zeiss, Jena, Germany)
Statistical analysis
Test results are expressed as a percentage of the control
as mean and SD. Differences in results were evaluated for
significance using Student’s t-test. Statistical significances
of differences were indicated as * P<0.01, ** P<0.001,
*** P<0.0001.
III. Results
Effects of sevoflurane on cell viability and morphological 
characteristics of primary cultured neurons
The viability of sevoflurane-treated primary cultured
neurons was examined. Neuronal cells were treated with 0.5
mM sevoflurane for various times (0, 3, 30, 60, 120 min) as
illustrated in Figure 1A, and with 120 min sevoflurane vari-
ous concentrations (0, 0.25, 0.5 mM) as illustrated in Figure
1B. Sevoflurane did not affect the cell viability. In addition,
at the light microscopic level, the cells appeared healthy and
without vacuolation or other evidence of damage (Fig. 1C
and D). These results demonstrated that sevoflurane has no
detectable cytotoxicity and does not significantly stimulate
primary cultured neurons.
Immunoblot analysis for PKC isoforms in the cytosol and 
membrane fractions
One of the characteristics of PKC signaling is the trans-
location of the PKC from the cytosol to the membrane frac-
tion. The effects of sevoflurane on the translocation of PKC
isoforms in cultured fetal rat cerebral cortex neurons were
examined by immunoblotting using PKC isoform-specific
antibodies. PKC isoforms (α, βI, βII, γ, δ, ε and ζ) were
enriched in the cytosol fraction compared with the mem-
brane fraction under the control conditions (Fig. 2). Treat-
ment with sevoflurane induced the translocation of PKC α
and βII species from the cytosol to the membrane fraction
which indicated the activation of these isoforms. However
there were no clear changes in the distribution of PKC βI, γ,
δ, ε or ζ in sevoflurane-treated neuronal cells. The quantita-
tive analysis of PKC isoforms in the cytosol and membrane
fractions are shown in Figure 3. When neuronal cells wereHasegawa et al. 166
treated with sevoflurane for various times (2.5, 5, 10, 15, 30,
60, 120 min), significant increases of the relative amount of
PKC α and βII isoforms in membrane fraction and decreases
in the cytosol fraction occurred in a time-dependent manner
(Fig. 3A, C).
Sevoflurane enhances the phosphorylation of Raf, MEK and 
ERK1/2 in neuronal cells
We next examined whether the specific activation of
PKC α and βII by sevoflurane stimulated the MAP kinase
signaling pathway in cultured fetal rat cerebral cortex neu-
rons (Figs. 4 and 5). An increase of Raf phosphorylation was
observed within 2.5 ml of the administration of 0.25 mM
Fig. 1. Morphological characteristics and cell viability of rat cerebral cortex cultured neurons following treatment with sevoflurane. Cell viabil-
ity was measured as described in Materials and Methods. Results are presented as the mean±SD of five determinations (A and B). Phase contrast
light micrographs of primary cultured neurons treated with DMSO (control) (C) or 0.5 mM sevoflurane (D) for 2 hr. The statistical significance
of differences was evaluated using Student’s t-test with a level of P<0.05 being considered significant. The differences in cell viability were not
significant.
Fig. 2. Effect of sevoflurane on subcellular localization of specific
PKC isoforms in rat cerebral cortex cultured neurons. Cultured neu-
rons were incubated at 37°C for 0, 15, 60 or 120 min in the presence
of 0.25 mM sevoflurane, and then separated into the cytosolic and
membrane fraction (cytosol protein 10 µg; membrane protein 30 µg)
in triplicate. These fractions were separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes and immunoblotted with anti-
body to PKC α, βI, βII, γ, δ, ε or ζ. The portion of the immunoblot
containing PKC immunoreactive bands (Mr=80000–82000) is
shown for clarity.Sevoflurane Stimulates PKC/MAPK Signaling 167
Fig. 3. Quantitative time-course analysis of subcellular distribution of PKC isoforms in rat cerebral cortex cultured neurons exposed to 0.25 mM
sevoflurane for 0, 15, 60 or 120 min (A: PKC α, B: PKC βI, C: PKC βII, D: PKC γ, E: PKC δ, F: PKC ε, G: PKC ζ). Band intensities were
measured by densitometry. Values are expressed as the mean±SD of five determinations (n=5). Significance of differences was determined by
Student’s t-test; * P<0.01, ** P<0.001.Hasegawa et al. 168
sevoflurane (Fig. 5A). Subsequently, the level of phosphory-
lated MEK protein was increased at 10–15 min after sevo-
flurane treatment (Fig. 5C). In addition, the phosphorylation
of ERK1/2 protein reached a maximum at 15–90 min (Fig.
5E). In contrast, the contents of total Raf, MEK and ERK1/2
proteins were relatively constant at all times examined (Fig.
5B, D, F). These data demonstrate that the activation of the
MAP kinase cascade occurred after sevoflurane administra-
tion in neuronal cells.
Fig. 5. Time course of Raf, MEK and ERK activation by sevoflurane. Cultured neurons were incubated at 37°C for 0, 2.5, 5, 10, 15, 30, 60, 90
or 120 min in the presence of 0.25 mM sevoflurane (A: Raf, B: pRaf, C: MEK, D: pMEK, E: ERK, F: pERK). Band intensities were measured
by densitometry. Each value is expressed as the mean±SD of five determinations (n=5). The significance of differences was determined by
Student’s t-test; * P<0.01, ** P<0.001, *** P<0.0001.
Fig. 4. Time course of sevoflurane-induced phosphorylation of Raf,
MEK and ERK proteins. Cultured neurons were incubated at 37°C
for 0, 2.5, 5, 10, 15, 30, 60, 90 or 120 min in the presence of 0.25
mM sevoflurane. Total cell lysates were assessed by immuno-
blotting analysis with antibodies against the phosphorylated and
unphosphorylated forms of Raf, MEK and ERK1/2. pRaf, phospho-
rylated Raf; tRaf, total Raf protein; pMEK, phosphorylated
MEK; tMEK, total MEK protein; pERK1/2, phosphorylated ERK;
tERK1/2, total ERK1/2 protein.Sevoflurane Stimulates PKC/MAPK Signaling 169
Effects of staurosporine and PD98059 on sevoflurane-
induced ERK phosphorylation
The PKC inhibitor (staurosporine: 100 nM) and MEK
inhibitor (PD98059: 20 µM) significantly decreased the
phosphorylation of ERK1/2 induced by sevoflurane treat-
ment (Fig. 6). This result strongly demonstrated that the
sevoflurane-induced ERK1/2 phosphorylation mediated by
the activation of PKC and MEK in fetal rat cerebral cortex
cultured neuron.
Immunohistochemistry
In order to examine the localization of phosphorylated-
ERK1/2 (pERK1/2) protein, immunohistochemical studies
of sevoflurane-treated cultured neuronal cells were per-
formed. In control neurons at 0 min after sevoflurane treat-
ment, the cell bodies were weakly stained with antibody spe-
cific for the pERK1/2 protein (Fig. 7). pERK1/2 proteins
were remarkably increased in both the cell body and the
neurites after 0.25 mM sevoflurane-treatment.
IV. Discussion
Volatile anesthetics, including halothane, isoflurane
and sevoflurane, produce behavioral effects associated with
altered neuronal functions [14]. Despite the widespread use
of these anesthetics, their mechanism of action via their
effects on intracellular signaling pathways remains obscure.
The PKC family comprises signal transduction enzymes
consisting of several isoforms which are highly concentrated
in the nervous system and have been implicated in the mod-
ulation of neuronal synaptic transmission [9, 19, 21]. Fur-
thermore, many studies have implicated PKC as a potential
target for general anesthetic effects in various tissues. In
addition, it is well documented that PKC is an important ini-
tiator of the MAP kinase signaling, which is considered to
mediate numerous cellular functions such as proliferation,
differentiation and also volatile anesthetic-induced pharma-
cological preconditioning [27]. However, the effects of vol-
atile anesthetics on PKC and MAP kinase signaling, espe-
cially which PKC molecules are responsible, in neuronal
cells remain unclear. The results of this study clearly demon-
strated that in cultured neurons from the rat cerebral cortex,
a volatile anesthetic, sevoflurane, induced the phosphoryla-
tion of a series of proteins related to MAP kinase signaling,
including Raf, MEK and ERK1/2. This sevoflurane-induced
activation of the MAP kinase pathway was initiated by the
isoform-specific activation of PKC α and βII, which are
Ca2+-dependent PKC molecules.
Phosphorylation of specific proteins is a key biochemi-
cal reaction in the regulation of many aspects of neuronal
function. Various lines of evidence have implicated PKC-
mediated protein phosphorylation as a target for general
anesthetic effects in the central nervous system [4, 23]. In
vitro biochemical experiments have demonstrated that gen-
eral anesthetics directly affect PKC activity [4, 5, 23, 28].
Those studies demonstrated the ability of volatile anesthetics
and intravenous anesthetics to induce significant increases in
the sensitivity of purified brain PKC to its endogenous acti-
vators phosphatidylserine, diacylglycerol, and Ca2+ in vitro.
Eleven isoforms of PKC have been identified in mammalian
tissues. Individual PKCs mediate different biological pro-
cesses in the cell, and accordingly these isoforms differ in
their tissue distribution, regional distribution in the brain,
subcellular localization, and sensitivity to various activators
[2, 24]. Previous studies using isoform-selective antibodies
to PKC α, PKC β or PKC γ demonstrated that halothane, a
volatile anesthetic, promotes the translocation of the three
conventional PKC isoforms from the cytosol to the mem-
brane fraction of synaptosomes [7]. On the other hand,
Zhong and Su reported the activation of novel PKC ε but not
of conventional PKC α by isoflurane in vascular smooth
muscle cells [29]. They also showed that isoflurane-acti-
vated ERK1/2 in cultured smooth muscle cells is initiated by
novel PKC. Furthermore, in rat heart, PKC δ and PKC ε
mediate isoflurane-induced preconditioning [12]. These
reports indicated that volatile anesthetics activate specific
PKC isoforms in various tissues under certain conditions. In
the present study, one of our objectives was to identify the
PKC isoforms activated by sevoflurane in cultured neurons
derived from the rat cerebral cortex. We also assessed the
intracellular localization of individual PKC isoforms before
and after treatment with sevoflurane. The major finding of
the current study was that sevoflurane specifically activates
PKC α and PKC βII, resulting in their translocation to dis-
tinct intracellular sites in rat cerebral cortex cultured neu-
rons, as demonstrated using isoform-selective antibodies to
PKC α, PKC βI, PKC βII, PKC γ, PKC δ, PKC ε and PKC
Fig. 6. Effects of staurosporine and PD98059 on sevoflurane-
induced ERK1/2 phosphorylation. Staurosporine: 100 nM, PD98059:
20 µM, sevoflurane: 0.25 mM. Mean±SD (n=5). pERK1/2 levels
are expressed as a percentage of the control. * P<0.01, ** P<0.001
compared with control. The PKC inhibitor, staurosporine and MEK
inhibitor, PD98059, significantly decreased sevoflurane-induced
ERK phosphorylation.Hasegawa et al. 170
ζ. This result suggests that PKC α and PKC βII molecules
have an important role in the function of volatile anesthetics
in neuronal cells. Hemmings et al. demonstrated that halo-
thane had no significant effects on PKC γ translocation,
while significant effects of halothane were observed on the
distributions of PKC α and β in cytosol and membrane [7].
This report suggested that volatile anesthetics stimulated the
translocation process itself, perhaps by increasing the affin-
ity of activated PKC for its specific membrane receptor in
particular cells.
It has been reported that high levels of activation of
PKC can cause neurodegeneration and are consistent with
the possibility that altered cellular signaling contributed to
pathological neuronal degeneration in cultured human corti-
cal neurons [13]. Moreover, it has been reported that PKC δ
is involved in nitric oxide-induced dopaminergic cell death
[11]. These reports clearly suggested that altered intracellu-
lar signaling, such as over-activation of PKCs, elicit neu-
ronal cell degeneration. In this study, it became apparent that
the treatment of sevoflurane induced the activation of PKC
α and βII specifically. Nevertheless, data on cell viability
after sevoflurane treatment further demonstrated that there is
no detectable cytotoxicity of fetal rat cerebral neurons in re-
sponse to sevoflurane in the range of 0.25–0.5 mM for 2 hr.
Fig. 7. Immunohistochemical localization of phosphorylated-ERK in sevoflurane-treated fetal rat cerebral cultured neurons. After treatment
with 0.25 mM sevoflurane, cultured neurons were fixed and immunohistochemistry was performed. Immunohistochemical localization of green
reaction for pERK. Blue color indicates the nucleus. Bar=25 µM.Sevoflurane Stimulates PKC/MAPK Signaling 171
This is the first study to assess the effects of sevoflu-
rane on the MAP kinase cascade in rat cerebral cortex neu-
rons. Activation of PKC affects several downstream targets
including MAP kinase cascade proteins. Among the MAP
kinase cascade, ERK1/2 was found to be involved in volatile
anesthetic-induced preconditioning [12]. In addition, isoflu-
rane increased ERK1/2 phosphorylation in cultured vascular
smooth muscle cells, and this ERK1/2 signaling is down-
stream of PKC signaling [29]. The activation of MAP kinase
signaling is regulated by phosphorylation, and this process
was shown to be PKC-dependent. In the present study,
we investigated the MAP kinase signaling in sevoflurane-
treated neuronal cells. Sequential phosphorylation of MAP
kinase proteins, such as Raf, MEK, and ERK, resulted from
the treatment with sevoflurane and the subsequent PKC acti-
vation. Furthermore, the phosphorylation of ERK induced
by sevoflurane was significantly decreased by the treatment
of staurosporine (PKC inhibitor) and PD98059 (MEK inhib-
itor). From these results, it is concluded that isoform-
specific PKC activation may elicit sequential activation of
various steps of the MAP kinase pathway. Furthermore,
this result also suggests that MAP kinase signaling may be
involved in the anesthetic function in the brain. To examine
the intracellular localization of activated (phosphorylated)-
MAP kinase proteins before and after exposure to sevo-
flurane, immunohistochemical analysis of phosphorylated-
ERK1/2 (pERK1/2) protein was performed using phospho-
rylation specific antibody. In the cell body and neurites of
cerebral cortex neurons, the phosphorylation of ERK1/2
was increased in a time-dependent manner after sevoflurane
treatment and returned toward the baseline level at 90 min.
pERK1/2 was localized in the cytosol region of the cell body
and in neurites. These results clearly demonstrate that the
volatile anesthetic sevoflurane activate the MAP kinase
pathway in rat cerebral cortex cultured neurons. The volatile
anesthetic isoflurane reduces acute and delayed neuron
death in in vitro models of brain ischemia [3]. This isoflu-
rane-induced neuroprotection requires the phosphorylation
of the components of MEK-ERK pathway. In addition, the
activation of PKC ε and ERK1/2 is important for cardio-
protection by volatile anesthetic desflurane-induced pre-
conditioning. Taken together, these findings suggest that
the activation of MAP kinase signaling via PKC is crucial
for volatile anesthetic-induced cell protection.
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